RT Journal Article
SR Electronic
T1 Scleroderma lung disease: A scleroderma physiologic index (SPI) derived from lung physiology and oxygen saturation
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P5119
VO 42
IS Suppl 57
A1 Katerina Antoniou
A1 David Hansell
A1 Nicole Goh
A1 Katerina Samara
A1 Elizabeth Renzoni
A1 Maher Toby
A1 Nikos Siafakas
A1 Athol Wells
YR 2013
UL http://erj.ersjournals.com/content/42/Suppl_57/P5119.abstract
AB The quantitation of disease severity in Scleroderma Lung (SSc-ILD) using pulmonary function tests is often confounded by emphysema. We identified the scleroderma physiologic index (SPI) with readily available measures (spirometry, diffusion capacity and oxygen saturation).Consecutive patients with a clinical/computed tomography diagnosis of scleroderma lung (n = 292) were divided into group I (n = 146) and group II (n = 146). Cohort 1 (derive cohort) and 2 (test cohort) did not differ in outcome, PFTs, age, gender, smoking status at baseline. There were 55 /146 deaths in cohort 1 and 50/146 deaths in cohort 2. The formula has been derived in cohort 1 and then calculated in test cohort 2. The SPI was derived in group I (by fitting pulmonary function tests against disease extent on CT) and was tested in Group II (test cohort). The formula for the SPI was as follows: 384.0 – (0.37x percent predicted diffusing capacity for carbon monoxide [DLCO]) – (0.59x percent predicted FVC) + 0.72x percent predicted FEV1) = (3.46 x saturation). In the test cohort, the SPI (median 40.9, range 9.2 to 82) was strongly predictive of mortality (HR 1.07, CI 1.04 -1.10, p<0.0005). SPI calculated from final formula and shown to predict survival more strongly than DLco, FVC, FEV1, Po2, Aag, satn, Kco or CPI. The SPI was always predictive of mortality and after inclusion of the SPI, no other variable was independently predictive of mortality. The SPI provides an easily calculated pulmonary function index, validated against mortality and potentially useful in the parametric quantification of disease severity, both for clinical purposes and to adjust for disease severity in clinical research.